文献速递浆细胞疾病造血干细胞移植与细胞治疗

卡非佐米、来那度胺和地塞米松联合移植治疗新诊断多发性骨髓瘤

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
PubMed 文献 · Blood · 2020-01-01

这项2期多中心研究评估卡非佐米-来那度胺-地塞米松(KRd)方案联合自体干细胞移植(ASCT)治疗新诊断多发性骨髓瘤(NDMM),主要终点为8周期后严格完全缓解(sCR)率,预设阈值≥50%。76例患者入组,中位年龄59岁,35.5%伴高危细胞遗传学。8周期后sCR率60%,达到主要终点;中位随访56个月,意向治疗(ITT)人群5年无进展生存(PFS)率和总生存(OS)率分别为72%和84%。

要点

  • KRd联合ASCT在NDMM中8周期后sCR率60%,达到预设≥50%的阈值。
  • 中位随访56个月,ITT人群5年PFS率72%、OS率84%。
  • 微小残留病(MRD)阴性患者5年PFS率85%、OS率91%,高危细胞遗传学患者分别为57%和72%。

核心结论

  • NDMM患者接受KRd联合ASCT在KRd巩固治疗结束时获得高sCR率和MRD阴性率,巩固后延长KRd维持治疗有助于加深缓解并可能延长PFS和OS,安全性和耐受性可控。

研究设计与样本

  • 2期多中心研究,纳入适合移植的NDMM患者76例,中位年龄59岁(范围40-76岁),35.5%伴高危细胞遗传学。
  • 治疗方案为4周期KRd诱导、ASCT、4周期KRd巩固和10周期KRd维持。
  • 主要终点为8周期KRd后sCR率,预设阈值≥50%以支持进一步研究。

主要发现

  • 8周期后sCR率为60%,达到主要终点;按ITT分析sCR率达76%。
  • 改良ITT人群二代测序(灵敏度<10⁻⁵)MRD阴性率为70%。
  • 中位随访56个月,ITT人群5年PFS率72%、OS率84%;MRD阴性患者5年PFS率85%、OS率91%;高危细胞遗传学患者5年PFS率57%、OS率72%;高危且MRD阴性患者5年PFS率77%、OS率81%。
  • 3-4级不良事件包括中性粒细胞减少(34%)、淋巴细胞减少(32%)、感染(22%)和心脏事件(3%);无3-4级周围神经病变。

关键数值与推荐

  • 主要终点预设sCR率阈值≥50%。
  • 8周期后sCR率60%,ITT分析sCR率76%,改良ITT分析MRD阴性率70%(二代测序,灵敏度<10⁻⁵)。
  • 3-4级中性粒细胞减少34%、淋巴细胞减少32%、感染22%、心脏事件3%;无3-4级周围神经病变。

临床怎么用

  • 作者认为KRd联合ASCT在NDMM中可获得高sCR率和MRD阴性率,巩固后延长KRd维持治疗有助于加深缓解并可能延长PFS和OS,安全性和耐受性可控。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this phase 2 multicenter study, we evaluated the incorporation of autologous stem cell transplantation (ASCT) into a carfilzomib-lenalidomide-dexamethasone (KRd) regimen for patients with newly diagnosed multiple myeloma (NDMM). Transplant-eligible patients with NDMM received 4 cycles of KRd induction, ASCT, 4 cycles of KRd consolidation, and 10 cycles of KRd maintenance. The primary end point was rate of stringent complete response (sCR) after 8 cycles of KRd with a predefined threshold of ≥50% to support further study. Seventy-six patients were enrolled with a median age of 59 years (range, 40-76 years), and 35.5% had high-risk cytogenetics. The primary end point was met, with an sCR rate of 60% after 8 cycles. Depth of response improved over time. On intent-to-treat (ITT), the sCR rate reached 76%. The rate of minimal residual disease (MRD) negativity using modified ITT was 70% according to next-generation sequencing (<10-5 sensitivity). After median follow-up of 56 months, 5-year progression-free survival (PFS) and overall survival (OS) rates were 72% and 84% for ITT, 85% and 91% for MRD-negative patients, and 57% and 72% for patients with high-risk cytogenetics. For high-risk patients who were MRD negative, 5-year rates were 77% and 81%. Grade 3 to 4 adverse events included neutropenia (34%), lymphopenia (32%), infection (22%), and cardiac events (3%). There was no grade 3 to 4 peripheral neuropathy. Patients with NDMM treated with KRd with ASCT achieved high rates of sCR and MRD-negative disease at the end of KRd consolidation. Extended KRd maintenance after consolidation contributed to deepening of responses and likely to prolonged PFS and OS. Safety and tolerability were manageable. This trial was registered at www.clinicaltrials.gov as #NCT01816971.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Jasielec JK, Kubicki T, Raje N, et al. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood. 2020. PMID: 32735641. doi:10.1182/blood.2020007522

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。